VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-577-3600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.25 million
Profitability
Miscellaneous
Employees9
Next Earnings Date8/27/2019 (Estimated)
OptionableNot Optionable
Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions
What is Vistagen Therapeutics' stock symbol?
Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."
How were Vistagen Therapeutics' earnings last quarter?
Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its quarterly earnings data on Tuesday, February, 12th. The company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.03. View Vistagen Therapeutics' Earnings History.
When is Vistagen Therapeutics' next earnings date?
What price target have analysts set for VTGN?
3 equities research analysts have issued 1 year target prices for Vistagen Therapeutics' shares. Their predictions range from $0.70 to $6.00. On average, they anticipate Vistagen Therapeutics' share price to reach $4.2333 in the next year. This suggests a possible upside of 600.7% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.
What is the consensus analysts' recommendation for Vistagen Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vistagen Therapeutics.
What are Wall Street analysts saying about Vistagen Therapeutics stock?
Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
- 1. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019)
- 2. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/11/2019)
- 3. Maxim Group analysts commented, "VistaGen announced that it has expanded its partnership with Pherin Pharmaceuticals (private) and acquired rights for PH10, a pherin steroid in a nasal spray formulation. Recall that 3-ready pherin steroid for social anxiety disorder, was acquired from Pherin Pharmaceuticals last month." (10/25/2018)
Has Vistagen Therapeutics been receiving favorable news coverage?
News headlines about VTGN stock have trended positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vistagen Therapeutics earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Vistagen Therapeutics.
Who are some of Vistagen Therapeutics' key competitors?
Some companies that are related to Vistagen Therapeutics include AgeX Therapeutics (AGE), Avenue Therapeutics (ATXI), Verastem (VSTM), Correvio Pharma (CORV), Eton Pharmaceuticals (ETON), Abeona Therapeutics (ABEO), Neos Therapeutics (NEOS), Millendo Therapeutics (MLND), Savara (SVRA), Aquestive Therapeutics (AQST), Processa Pharmaceuticals (PCSA), Sunesis Pharmaceuticals (SNSS), Iterum Therapeutics (ITRM), Tiziana Life Sciences (TLSA) and Alpine Immune Sciences (ALPN).
What other stocks do shareholders of Vistagen Therapeutics own?
Who are Vistagen Therapeutics' key executives?
Vistagen Therapeutics' management team includes the folowing people:
- Mr. Shawn K. Singh, CEO & Director (Age 56)
- Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
- Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
- Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
- Dr. Mark A. Smith, Chief Medical Officer (Age 64)
Who are Vistagen Therapeutics' major shareholders?
Vistagen Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.81%), HighTower Advisors LLC (0.31%), D.A. Davidson & CO. (0.19%), Wells Fargo & Company MN (0.10%) and LPL Financial LLC (0.09%). View Institutional Ownership Trends for Vistagen Therapeutics.
Which major investors are selling Vistagen Therapeutics stock?
Which major investors are buying Vistagen Therapeutics stock?
How do I buy shares of Vistagen Therapeutics?
Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vistagen Therapeutics' stock price today?
One share of VTGN stock can currently be purchased for approximately $0.6042.
How big of a company is Vistagen Therapeutics?
What is Vistagen Therapeutics' official website?
How can I contact Vistagen Therapeutics?
Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]
MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
